Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer

MA Villalona-Calero, MG Wientjes, GA Otterson… - Clinical cancer …, 2003 - AACR
Purpose: Our preclinical studies have shown that acidic and basic fibroblastic growth factors
confer broad spectrum chemoresistance and that low concentrations (10–50 μm) of suramin …
被引用次数：61 相关文章

Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer

MA Villalona-Calero, MG Wientjes… - … : an official journal …, 2003 - pubmed.ncbi.nlm.nih.gov
Purpose Our preclinical studies have shown that acidic and basic fibroblastic growth factors
confer broad spectrum chemoresistance and that low concentrations (10-50 microM) of …

[引用][C] Phase I study of low-dose suramin as a chemosensitizer in Patients with advanced non-small cell lung cancer

MA VILLALONA-CALERO… - Clinical cancer …, 2003 - pascal-francis.inist.fr
Phase I study of low-dose suramin as a chemosensitizer in Patients with advanced non-small
cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.

MA Villalona-Calero, MG Wientjes… - … Cancer Research: an …, 2003 - europepmc.org
Purpose Our preclinical studies have shown that acidic and basic fibroblastic growth factors
confer broad spectrum chemoresistance and that low concentrations (10-50 microM) of …

Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer

MA Villalona, MG Wientjes… - Clinical Cancer …, 2003 - ohiostate.elsevierpure.com
Purpose: Our preclinical studies have shown that acidic and basic fibroblastic growth factors
confer broad spectrum chemoresistance and that low concentrations (10-50 μM) of suramin …